| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02528877 Details | 2016-09-14 Interventional | 1 | 0 | Fludarabine Fludarabine pho… Mechlorethamine Melphalan Nitrogen Mustar… Sirolimus Tacrolimus Graft vs Host D… Leukemia Leukemia, Myelo… Leukemia, Myelo… Neoplasm Metast… Primary Myelofi… Acute Myeloid L… Primary Myelofi… Secondary Acute… Secondary Myelo… | The study design was revised so a new protocol will be opened. - | |||
| NCT01865175 Details | 2016-09-14 Interventional | 4 | 0 | Iron Iron Deficienci… Iron Deficiency | Institution required IND, although FDA did not, so institution did not allow enrollment - | |||
| NCT01077947 Details | 2016-09-13 Interventional | 4 | 0 | Anesthetics Back Pain Low Back Pain Discogenic Pain | Internal - | |||
| NCT01121757 Details | 2016-09-12 Interventional | 2 | 11 | Azacitidine Lenalidomide Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Follicular Lymp… Marginal Zone L… | The study closed temporarily in February 2012 pending analysis of samples collected. In
October, 2012, Celgene requested closure of the study. - | |||
| NCT00190476 Details | 2016-09-12 Interventional | 3 | - | Docetaxel Carcinoma, Non-… Lung Neoplasms Non-small-cell … | - - | |||
| NCT02894554 Details | 2016-09-09 Interventional | 4 | 19 | Lamivudine Telbivudine HBsAg-positive … | clinical myalgia - | |||
| NCT02654730 Details | 2016-09-09 Interventional | 2/3 | 61 | Artemisinins Artenimol Piperaquine Primaquine Malaria | Enrollment took longer than anticipated; it was financially and logistically impossible to
recruit the final cohort (G6PDd 0.4mg/kg PQ). - | |||
| NCT00922532 Details | 2016-09-09 Interventional | 3 | 0 | Nitric Oxide Hypertension Hypertension, P… Hypoxia Respiratory Ins… Hypoxic Respira… | Company decision not to pursue prior to submission - | |||
| NCT02222207 2012-003763-22 Details | 2016-09-08 Interventional | 2 | 52 | Ranibizumab Macular Degener… Wet Macular Deg… | - As the study was prematurely terminated since pre-defined proof of concept (PoC) criteria were not met in Part A, hence part B was not initiated. Part B related end points and data were not reported since it is not conducted. | |||
| NCT00973271 Details | 2016-09-01 Interventional | 3 | 0 | Atorvastatin Fenofibrate Fenofibric acid Hypertriglyceri… | Did not continue with development of DCCR in Very High Triglycerides - | |||
| NCT00901823 Details | 2016-09-01 Interventional | 1 | 0 | Choline Diazoxide Hypertriglyceri… | Did not support the planned development of DCCR in the new indication - | |||
| NCT01882387 Details | 2016-08-31 Interventional | 2 | 0 | Angiotensin I (… Graft vs Host D… Hematologic Neo… Hematologic Mal… | Change in drug product development strategy - | |||
| NCT01882374 Details | 2016-08-31 Interventional | 2 | 0 | Angiotensin I (… Graft vs Host D… Hematologic Neo… Hematologic Mal… | Change in drug product development strategy - | |||
| NCT01584362 Details | 2016-08-30 Interventional | 1 | [3 Refs] | 0 | Oxfendazole Neurocysticerco… Taeniasis Tenia Solium In… | study conducted under Clinical Trials Agreement as NIAID registration NCT02234570 - | ||
| NCT00676559 Details | 2016-08-26 Interventional | 1 | 0 | Ranibizumab Edema Macular Edema Diabetic Macula… | Unrelated serious adverse events involving one of the proposed medications - | |||
| NCT02876770 Details | 2016-08-24 Interventional | 1 | 12 | Melatonin Motor Activity | - - | |||
| NCT02120274 Details | 2016-08-24 Interventional | 4 | 85 | Hydroxocobalami… Vitamin B 12 Vitamin D Vitamins Communicable Di… Flaviviridae In… Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Infections RNA Virus Infec… Virus Diseases | New Brazilian Guidelines for Viral Hepatitis C and Coinfetions. It does not include the
treatment of chronic HCV Metavir < F3 and abandon the use of interferon. - | |||
| NCT02030574 Details | 2016-08-24 Interventional | 2 | 2 | Gemcitabine Urinary Bladder… Bladder Cancer Invasive Bladde… | The study is being closed to accrual secondary to low accrual and an interest in opening up a
different trial. The study has been terminated secondary to low accrual and an interest in opening up a different trial; more tailored to Physician interests and patient need. | |||
| NCT00404703 Details | 2016-08-24 Interventional | 2 | 37 | Bevacizumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Primary (safety) endpoint reached - | |||
| NCT00771056 Details | 2016-08-22 Interventional | 2 | 23 | Hydroxychloroqu… Leukemia Leukemia, Lymph… Leukemia, Lymph… B-Cell Chronic … | study suspended while data is reviewed for safety and efficacy. - |